ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02917200
Recruitment Status : Completed
First Posted : September 28, 2016
Last Update Posted : September 12, 2017
Sponsor:
Information provided by (Responsible Party):
Da Volterra

Brief Summary:
The purpose of this study is to evaluate whether different DAV132 dose regimens are safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Moxifloxacin Device: DAV132 Other: Negative control Phase 1

Detailed Description:

The aim of the study is to evaluate the performances of different DAV132 dose regimens in healthy volunteers:

  • To capture antibiotic residues in the colon without interfering with its systemic pharmacokinetics.
  • To prevent antibiotic-induced changes of the intestinal microbiota. In addition, the security of DAV132 given at different dose regimens during 7 days will be evaluated.

This is a prospective, randomized, controlled, repeated doses, 12 parallel groups, open-label study, blinded to analytical and microbiological evaluations.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Impact of Different DAV132 Dose Regimens (From 2 to 22.5 g/Day During 7 Days, Bid and Tid) on the Fecal Moxifloxacin Concentrations and the Intestinal Microbiota of Healthy Volunteers Treated With Moxifloxacin 400 mg/Day During 5 Days
Actual Study Start Date : May 11, 2016
Actual Primary Completion Date : December 2, 2016
Actual Study Completion Date : December 2, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: MOX + CTRL
Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
Drug: Moxifloxacin
Oral route

Other: Negative control
Oral route

Experimental: MOX + DAV132 7.5 g tid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 7.5 g bid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 5 g tid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 5 g bid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 3.3 g tid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 3 g bid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 2 g tid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 1.5 g bid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 1 g tid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

Experimental: MOX + DAV132 1 g bid
Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
Drug: Moxifloxacin
Oral route

Device: DAV132
Oral route

CTRL
Negative control, tid, 7 days
Other: Negative control
Oral route




Primary Outcome Measures :
  1. Area under the curve of free moxifloxacin fecal concentrations from D1 to D16 (AUC D1-D16) [ Time Frame: over 16 days after treatment start ]

Secondary Outcome Measures :
  1. Bacterial diversity of the intestinal microbiota (16S rDNA profiling) [ Time Frame: over 37 days after treatment start ]
  2. Area under the curve of moxifloxacin plasma concentrations from 0 to 24 hours (AUC0-24h) on D1 and D5 [ Time Frame: over 5 days after treatment start ]
  3. Maximum moxifloxacin plasma concentrations (Cmax) on D1 and D5 [ Time Frame: over 5 days after treatment start ]
  4. Number of adverse events and percentage of subjects with at least one adverse event [ Time Frame: over 37 days after treatment start ]
  5. Number of subjects with samples positive for treatment-emergent quinolone / fluoroquinolone-resistant Enterobacteriaceae [ Time Frame: over 37 days after treatment start ]
  6. Occurrence of Clostridium difficile infection, evaluated by identification of C. difficile in diarrheic stools [ Time Frame: over 37 days after treatment start ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adults (males and females), able to read and write, aged from 18 to 60 years old inclusive.
  2. Body mass index (BMI) 18.5 - 30 kg/m² inclusive.
  3. Considered as healthy individuals according to a comprehensive clinical assessment (detailed medical history and full physical examination).
  4. Normal vital signs after 10-min rest in supine position: systolic blood pressure 95 - 140 mmHg inclusive, diastolic blood pressure 45 - 90 mmHg inclusive and heart rate (pulse rate) 50 - 100 bpm inclusive. Out of range values can be accepted if judged clinically non relevant by the Investigator.
  5. Normal 12-lead ECG after 10-min rest in supine position: PR interval 120 - 220 msec exclusive, QRS complex <120 msec, and QT interval <430 msec if male or <450 msec if female.
  6. Normal hematology and blood biochemistry test results. Out of range values can be accepted if judged clinically non relevant by the Investigator excepted for potassium and magnesium for which normal values are required.
  7. Normal digestive transit, with at least one daily stool.
  8. Females participating in the study:

    • either must be of non-child bearing potential (surgically sterilized at least 3 months prior to inclusion, or postmenopausal). Menopause is defined as being over 60 years of age, or between 45 and 60 years of age and being amenorrheic for at least 2 years with plasma FSH levels >30 IU/L;
    • or must have a negative pregnancy test and be not breastfeeding at screening, and must use abstinence or a double contraception method during the treatment period and for an additional period of 2 weeks after the end of investigational treatment. The accepted double contraception methods include the use of a highly effective method of birth control (intrauterine device or hormonal contraception) in addition to one of the following contraceptive options: (1) condom, (2) diaphragm or cervical/vault cap, (3) spermicide.
  9. Having given and signed the written study informed consent prior to undertake any study-related procedure.
  10. Covered by the French health insurance system.

Exclusion Criteria:

Criteria related to the healthy status

  1. Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, bone and joint, muscular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease; or signs of acute illness.
  2. Any history of relevant gastrointestinal disorders within three months prior to inclusion.
  3. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for each event, more than twice a month). Subject suffering from migraine on D1 will be excluded.
  4. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.

    Criteria specific to the study

  5. Contraindications to fluoroquinolones, or risk factors for adverse effects associated to fluoroquinolones as defined in the moxifloxacin Summary of Product Characteristics, and other than those already included into the inclusion/exclusion criteria: known hypersensitivity to fluoroquinolones, history of tendinopathy associated with fluoroquinolones, risk factor for tendinopathy / known tendon disorder, pregnancy, breast feeding, known history of myasthenia gravis, known history of / risk factors for QT interval prolongation (including close family history of arrhythmic disorders). Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase (G6PDH) deficiency should be excluded. Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should be excluded.
  6. Contraindications to charcoal, or risk factors for adverse events associated to charcoal other than those already included into the inclusion/exclusion criteria: known hypersensitivity to charcoal, risk of gastrointestinal obstruction, perforation or hemorrhage, recent digestive tract surgery.
  7. Fecal colonization by C. difficile.
  8. Recent history of hospitalization (within the last 3 months).
  9. Any antibiotic administration within the last 3 months.
  10. Any vaccination within the last 28 days.
  11. Blood donation, regardless of the volume, within 2 months before inclusion and during the study.
  12. Any previous administration of medication and any previous intake of herbal products known to interfere with drug metabolism such as St John's Wort within the last 14 days, with the exception of hormonal contraception or menopausal hormone replacement therapy or paracetamol.

    Criteria associated with addiction

  13. History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day).
  14. Smoking more than 5 cigarettes or equivalent per day (including nicotine-delivering devices such as patches, gums and electronic cigarettes), unable to stop smoking during the study.
  15. Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
  16. Positive result on urine drug screen (amphetamines / methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  17. Positive alcohol test. Administrative criteria
  18. Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  19. Any subject in the exclusion period of a previous biomedical research according to national law, and participation to any other clinical trial simultaneously.
  20. Any subject who cannot be contacted in case of emergency.
  21. Any subject who belongs to the Investigating Center staff.
  22. Subject of legal age unable to give consent
  23. Subject deprived of liberty by judicial or administrative decision
  24. Subject of legal age under legal protection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02917200


Locations
France
Eurofins Optimed
Gières, France, 38610
Sponsors and Collaborators
Da Volterra
Investigators
Principal Investigator: Yves Donazzolo Eurofins Optimed

Responsible Party: Da Volterra
ClinicalTrials.gov Identifier: NCT02917200     History of Changes
Other Study ID Numbers: DAV132-CL-1004
2015-A01899-40 ( Registry Identifier: ID-RCB )
First Posted: September 28, 2016    Key Record Dates
Last Update Posted: September 12, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Moxifloxacin
Fluoroquinolones
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors